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Abstract: Oral candidiasis (OC) is an increasing health problem due to the introduction of new
drugs, population aging, and increasing prevalence of chronic illness. This study systematically
reviews the effects of the oral intake of probiotics, prebiotics, and synbiotics on Candida spp. counts
(colony-forming units (CFU)/mL) in oral and palatal samples. A literature search was conducted.
Twelve studies, eight randomized clinical trials (RCTs), and four pre-post studies, resulted as eligible
for the meta-analysis, which was performed through a Bayesian random-effects model. All studies
analyzed probiotics, and none of them analyzed prebiotics or synbiotics. The treatments effects were
measured in terms of odds ratio (OR) of OC (CFU/mL >102, 103, or 104). The meta-analytic OR was
0.71 (95% credibility interval (CrI): 0.37, 1.32), indicating a beneficial effect of treatment; the I2 index
was 56.3%. Focusing only on RCTs, the OR was larger and more precise at 0.53 (95% CrI: 0.27, 0.93).
The effect of treatment appeared to be larger on denture wearers. Our findings indicate that the
intake of probiotics can have a beneficial effect on OC and that the effects could vary according to
the patients’ characteristics. Due to the presence of medium–high-risk studies, the results should be
interpreted with caution.
Keywords: Candida spp.; oral candidiasis; Candida spp. treatment; Candida spp. prevention;
Candida spp. carriage; probiotics; microbiota; Bayesian meta-analysis
1. Introduction
Candida spp. represent a commensal yeast belonging to the normal microbiota localized on the
surface of different body sites (skin, oral cavity, and the gastro-intestinal, uro-genital, and respiratory
tracts) of human beings [1]. Candida spp. colonization of the mucus membranes occurs very early
in life, usually at birth [2]. Under specific conditions, the fungus can switch from a harmless form
into a pathogenic form that can lead to infections [3]. About 75% of healthy adults carry Candida spp.
in the mouth; when there is a detection of a salivary Candida spp. count >400 colony-forming units
(CFU) per mL, an infection occurs called “oral candidiasis” (OC) [4]. OC is predominantly caused by
Candida albicans and by other species like Candida parapsilosis, Candida metapsilosis, Candida tropicalis,
Candida khmerensis [5], Candida glabrata [6], and Candida dubliniensis [7]. Using a clinical evaluation,
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we can identify different Candida spp. infection phenotypes: pseudomembranous, erythematous,
hyperplastic, angular cheilitis, median rhomboid glossitis [8,9], denture stomatitis [10], and linear
gingival erythema [11]. All these conditions can determine a widespread spectrum of symptoms
ranging from asymptomatic to very severe (such as burning sensation, pain, lesions, and bleeding),
leading to discomfort in mastication, thereby limiting the food intake.
OC incidence is growing in the last few decades, because of the increase in some immune-correlated
chronic illnesses (diabetes, cancer, human immunodeficiency virus (HIV)) and the intensive use of
some drugs, such as antibiotics, chemotherapy, and immunosuppressants [12]. Some of major factors
contributing to OC development are summarized in Table 1.
Table 1. Factors related to oral candidiasis (OC).
Factors Related to Oral Candidiasis
Iatrogenic factors
Antineoplastic agents [12]
Broad-spectrum antibiotics [13]
Inhaled corticosteroids [14]
Substance abuse [15,16]
Health conditions
Anemia [17]
Immunosuppression status [18]
Nutritional deficiencies [13]
Xerostomia [19]
Diseases
Cancer [20]
Cushing syndrome [13]
Diabetes mellitus [21,22]
Human immunodeficiency virus (HIV) [23]
Other factors
Age [17]
Denture wearing [20]
Pregnancy [24]
Smoke [16]
Sometimes, the superficial infection can spread out into the body, into the blood stream, causing
deep and invasive candidiasis, which is associated with high hospitalization rate and even mortality [13].
The available pharmacological treatments (e.g., antifungal drugs) are very effective but present some
critical points, such as frequent side effects and, in particular, antifungal resistance [1]. Therefore,
it would appear critical to develop new prophylactic and complementary therapeutic strategies.
The intake of probiotics seems a promising method in order to achieve these purposes. In fact, they
can modulate the gut microbiota and its cross-talk with immune response, with local (intestinal) and
systemic relapses [25–29].
Probiotics, that were identified and studied at the end of 19th century by various scientists
such as Metchnikoff, Tissier, Grigorov, and Shirota, are defined as “live microorganisms that, when
administered in adequate amount, confer health benefit to the host” [30]. The most used probiotics
belong to Lactobacillus spp. and Bifidobacterium spp. and, to a lesser extent, to Saccharomyces spp.,
Bacillus spp., and Escherichia spp. [31]. The beneficial proprieties of probiotics are supported by various
in vitro and in vivo studies, which used different bacterial strains (single or in combination), at different
dosages [31,32]. Various studies proved the preventive and therapeutic effects of good bacteria, some
of which involve metabolic functions such as fermentation of indigestible fibers [33], short-chain
fatty-acid production [34], lactose tolerance [35], vitamin production [36], and reduction of cholesterol
levels [37]. In addition, good bacteria have antimicrobial activity (such as competitive inhibition
of pathogens [38]), produce bacteriocins [39], have antitoxin effects [40], and enhance the intestinal
barrier function [41] (e.g., increased production of mucins, tight junction proteins, and goblet and
Paneth cells [42]). Finally, commensal bacteria exercise immune modulation (such as the stimulation
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of immunoglobulin A (IgA) production, increased production of anti-inflammatory cytokines, and
induction of regulatory T cells [42]).
These probiotics’ proprieties suggested their use for the treatment and prevention of many medical
conditions (diarrhea, constipation, inflammatory bowel disease, irritable bowel syndrome, allergic disease),
sometimes with excellent results [31]. In addition, probiotics also showed an antifungal action and were
successfully used in mucosal candidiasis, as reported in an in vivo study by Wagner in 1997 [43].
Sookkhee et al., in 2001, studied the effects on Candida albicans growth of different lactic-acid
bacteria isolated from the oral cavity of volunteers and found that two strains, Lactobacillus paracasei
and Lactobacillus rhamnosus, had the strongest effect on the yeast [44].
Lactobacillus reuteri is a promising bacterium (especially DSM 17938 and ATCC PTA 5289) for
its anti-Candida properties, confirmed by several studies. In one of these, Lactobacillus reuteri was
demonstrated to be able to reduce Candida load in vivo through co-aggregation, modification of oral
pH with production of lactic acid and other organic acids that inhibit the virulence of Candida cells,
and production of H2O2 [45].
In a recent in vitro study by Coman et al. (2014), the strains Lactobacillus rhamnosus IMC 501 and
lactobacillus paracasei IMC 502, alone or in combination, showed an inhibitory effect on Candida spp.
growth [46].
Lactobacillus delbrueckii ssp. bulgaricus B1 and Lactobacillus delbrueckii ssp. bulgaricus TAB2 were
found to fight Candida, releasing high amounts of lactic acid [47].
Recently, it was found that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 modulate
Candida glabrata virulence, through the complete inhibition of fungal biofilms [48].
In addition, Lactobacillus acidophilus ATCC 4356 was found to inhibit the biofilm formation
of fungus through in vitro experiments [49]. Biofilm formation is probably reduced through the
production of substances called “bacteriocins” by probiotics. Wannun et al. reported the isolation of a
bacteriocin, called “fermencin SD11”, from Lactobacillus fermentum SD11, a human oral Lactobacillus,
which has a strong inhibitory effect on oral Candida cells [50].
In 1997, Wagner et al. showed that the administration of probiotics could be a prophylactic
and therapeutic strategy for mucosal candidiasis [43]. They demonstrated that the presence of four
strains of bacteria (Lactobacillus acidophilus, Lactibacillus reuteri, Lactobacillus casei GG, and Bifidobacterium
animalis) in the gastro-intestinal tract of immunodeficient mice reduced the number of Candida albicans
cells, as well as the incidence and severity of mucosal and systemic candidiasis, prolonging their
survival [43].
In a murine model, Matsubara et al. inoculated Candida albicans in the oral cavity and subsequently
administrated an antifungal drug (nystatin) or probiotics (Lactobacillus acidophilus and Lactobacillus
rhamnosus). At the end of the experiment, colonization by yeast cells was lower in the group that
received probiotics (particularly L. rhamnosus) than in the group treated with nystatin [51].
In conclusion, even if the mechanism of probiotics’ antifungal effect remains to be fully elucidated,
some authors explored it in vitro and in vivo studies, showing that these bacteria may contrast Candida
spp. infection through different and synergistic mechanisms of action.
In this paper, we performed a systematic review and meta-analysis of clinical studies, randomized
controlled trials (RCT), and pre–post intervention studies, with the aim of investigating the efficacy of
probiotics (compared with a control treatment or placebo) on oral Candida spp. counts in subjects of
any age, sex, nationality, or health status.
2. Systematic Review and Meta-Analysis
2.1. Materials and Methods
2.1.1. Literature Search
The PRISMA statement guidelines were followed for conducting and reporting a systematic
review and meta-analysis [52].
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A computerized search of the articles published from inception to 1 February 2019, was conducted
in Embase, Medline/PubMed, Cochrane Library central, clinicaltrials.gov databases, and other
individual journals sources (Brazilian Dental Journal, Indian Journal of Health Sciences, and Biomedical
Research Kleu), using the following search string: (candidosis OR candidiasis OR oral Candida spp.
OR thrush OR yeast infection) AND (probiotic OR prebiotic OR yogurt OR synbiotic OR Lactobacillus OR
Bifidobacteria OR Saccaromyces OR Bacillus OR xylitol). In the PubMed database, we activated the filter
“Humans”; in Embase, we activated the filter “Research articles”; in Cochrane Library, we activated the
filter “Trials”; and, in clinicaltrials.gov, we activated the filter “recruitment: terminated or completed”.
No restrictions of language, country, duration of follow-up, and participants’ characteristics (race, age,
and sex) were imposed.
2.1.2. Study Selection
Two authors independently reviewed titles and abstracts of the collected articles, applying
pre-defined inclusion /exclusion criteria. The inclusion criteria were as follows:
(1) Randomized clinical trials or pre–post intervention studies;
(2) Availability of full text;
(3) Patients regardless of age, race, nationality, sex, and health status;
(4) Comparison between oral intake of probiotics, prebiotics, or synbiotics (of any type and dosage)
with a control treatment or a placebo in RCT; and between pre- and post-treatment conditions in
pre–post intervention studies;
(5) Outcome measurement expressed in CFU/mL of oral Candida spp. counts in saliva or palatal samples.
The exclusion criteria were as follows:
(1) Studies with fewer than 10 participants;
(2) Reviews, articles, and case reports;
(3) Studies with incomplete outcome data;
(4) Studies reporting results in a format which was not suitable for a meta-analysis, for example,
without Candida spp. counts/carriage.
2.1.3. Data Extraction
The same two authors performed the analysis of the full texts and the data extraction, with
the intervention of a third author in the case of poor agreement or discrepancies. Each reviewer
independently recorded data in a predefined data extraction form. The following data were obtained
from each selected trial: first author name, year of publication, study design, availability of a registered
study protocol, setting (institution, city, and country), characteristics of the studied population (mainly
age and health status), sample size, number of total participants at the end of follow-up, number of
subjects, number of subjects in the treatment and control groups (for RCTs), experimental treatment
(strain type or mixture type, dose in CFU/mL, and frequency of administration), control treatment,
inclusion and exclusion criteria, follow-up duration, characteristics of the sample, and outcome measure
expressed in Candida spp. counts (in CFU/mL).
2.1.4. Outcome Assessment
For each selected study, we calculated the odds ratio of OC (Candida spp. counts lower than a
threshold of 102, 103, or 104) of treated subjects versus controls, as a measure of treatment effect.
For seven RCTs (Hatakka et al. 2007 [52]; Ishikawa et al. 2015 [53]; Keller et al. 2018 [54]; Kraft-Bodi
et al. 2015 [55]; Li et al. 2014 [56]; Myazima et al. 2017 [57]; Petti et al. 2001 [58]), it was possible to
calculate the OR and its standard error from the 2 × 2 contingency table of the trial results. For the
RCT by Burton et al. 2013 [59], which reported a continuous outcome (mean of Candida spp. counts in
CFU/mL), we firstly calculated the standardized mean difference (SMD) between the treatment group
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and the control group; then, we derived the OR and the corresponding standard error according to
the Hasselblad and Hedges method [60]. The same approach was also used for two pre–post studies
(Rane et al. 2018 [61]; Sutula et al. 2013 [62]). In these cases, we assumed independence between pre
and post means, thus overestimating the standard errors.
Rane et al. (2008) [61] reported the results of separated analyses conducted on three different
samples of different age (50–59, 60–69, ≥70 years). A fixed-effects meta-analysis was performed on the
three results in order to obtain an overall combined estimate and the corresponding standard error.
Miyazima et al. (2017) [57] conducted an RCT with three treatment arms (placebo, treatment 1
with Lactobacillus acidophilus, and treatment 2 with Lactobacillus rhamnosus). We collapsed the results for
the two experimental treatments in order to obtain an overall OR of treatment vs. placebo.
For the pre–post studies by Lopez-Jornet et al. 2018 [63] and Mendonca et al. 2012 [64], which
reported the status of the patient in binary form, the McNemar OR was calculated [65].
2.1.5. Risk of Bias
The assessment of quality of the randomized clinical trials was performed using Review Manager
5.3 software, according to the Cochrane Handbook guidelines [66].
The two reviewers expressed, for each of the eight selected RCTs, their independent judgment
(low risk, high risk, or unclear) on the following domains: random sequence generation, allocation
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting, and other bias.
The assessment of quality of the pre–post intervention studies was performed using the quality
assessment tool for pre–post studies with no control group developed by the United States (US)
National Heart, Lung, and Blood Institute (NHLBI) [67].
In the case of disagreement between the two authors, a third investigator was involved to resolve
the controversy.
2.1.6. Statistical Analysis
A Bayesian random-effects meta-analysis model was specified to combine the results of the
selected studies and, successively, to combine the results from the subset of the RCTs [68]. Let bi be
the estimate of the log (OR) from the ith study, and si be the estimate of the corresponding standard
error (i = 1, 2, . . . , n). The random-effects meta-analysis assumes that the study-specific effects bi are
mutually independent and follow the following model:
bi = β + ui + εi, ui ~ N (0, τ2), εi ~ N (0, si2), (1)
where β is the overall meta-analytic effect, i is a random effect normally distributed with variance τ2, and
εi is an error term with known variance; ui and εi are assumed to be independent. The meta-analysis
model accounts for possible heterogeneity among studies through the random terms ui, and the
variance τ2 expresses the heterogeneity among studies. In the Bayesian formulation of the model, we
need to specify prior distributions. Two non-informative priors were specified on the hyperparameters
β and τ2.
We used MCMC methods to obtain a sample from the joint posterior distribution of the
parameters [69]. The posterior distribution of β was summarized in terms of mean and 95% credibility
interval (CrI), i.e., the 2.5th and 97.5th percentiles of the posterior distribution. The posterior distribution
of the I2 index, which expresses the percentage of total variance captured by τ2, was summarized in
terms of median and 95% CrI.
Sensitivity analyses were performed to evaluate the discrepancy between the results of the
meta-analysis on the RCTs and the results obtained excluding the two RCTs that enrolled only subjects
wearing dentures and the RCT that enrolled children.
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When the meta-analysis included fewer than three studies, a fixed-effects models was adopted
where only the within-study component of the variance was accounted for.
The presence of publication bias was evaluated by inspecting a funnel plot [70,71] and calculating
the Begg’s test [72]. All analyses were performed with R software (v3.5.1) [73] and the library
OpenBUGS (v3.0.7) [74].
2.2. Results
Study Selection
The initial search identified 2490 articles.
In total, 87 studies were excluded for duplication. Of the remaining 2403 papers, 2385 were
excluded after the screening for title and abstracts because they did not fulfil the inclusion criteria.
Among the 18 remained eligible articles, four were eliminated because the full text was not
available, the outcome was inappropriate, or the results were not reported. Finally, 12 studies were
included in the meta-analysis.
Figure 1 illustrates the selection process, according to the PRISMA statement 2009.
Nutrients 2019, 11, x FOR PEER REVIEW 6 of 21 
 
The presence of publication bias was evaluated by inspecting a funnel plot [70,71] and 
calculating the Begg’s test [72]. All analyses were performed with R software (v3.5.1) [73] and the 
library OpenBUGS (v3.0.7) [74]. 
2.2. Results 
2.2.1. Study Selection 
The initial search identified 2490 articles. 
In total, 87 studies were excluded for duplication. Of the remaining 2403 papers, 2385 were 
excluded after the screening for title and abstracts because they did not fulfil the inclusion criteria. 
Among the 18 remained eligible articles, four were eliminated because the full text was not 
available, the outcome was inappropriate, or the results were not reported. Finally, 12 studies were 
included in the meta-analysis. 
Figure 1 illustrates the selection process, according to the PRISMA statement 2009. 
 
Figure 1. PRISMA flow diagram. 
2.3. Characteristics of the Included Studies 
An overview of the included studies is reported in Table 2, which includes the reference, study 
design, setting, enrolled population, number of participants, intervention, comparison, follow-up, 
sample type, and outcome measurement.
 
Embase (n=2222) 
PubMed (n=105) 
Cochrane database (n=154) 
Records identified through  
databases searching 
(n=2481) 
 
 
 
Sc
re
en
in
g 
In
clu
de
d 
El
ig
ib
ili
ty
 
Id
en
tif
ica
tio
n 
Clinicaltrials.gov (n=4) 
Individual journals (n=5) 
Additional records identified  
through other sources 
(n=9) 
 
Records after duplicates removed 
(n = 2403) 
Records screened 
(n = 2403) 
Records excluded 
Because not relevant from 
title or abstracts 
(n =2385) 
Full-text articles assessed 
for eligibility 
(n = 18) 
 
Full-text articles excluded 
for: 
Not full-text 
Inappropriate outcome 
Missing data 
 
(n = 6) 
Studies included in 
qualitative synthesis 
(n = 12) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 12) 
    RCT    +    pre-post studies 
    (n=8)            (n=4) 
Figure 1. PRISMA flow diagram.
2.3. Char cteristics of the Included Studies
An overview of the included studies is re orte i able 2, which includes the reference, study
design, setting, enrolled population, nu ber of participants, intervention, comparison, follow-up,
sample type, and outcome measurement.
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Table 2. Overview of the included studies. RCT—randomized controlled trial; CFU—colony-forming unit; OR—odds ratio; CI—confidence interval.
Reference Study Design Setting Studied Population No. of Participants Intervention Comparison Follow-up Sample Type Outcome
Burton et al.
2013 [60] RCT
Schools with dental
clinics City: Dunedin
Country: New Zealand
Child population,
schoolchildren with
active caries. Age: 5
to 10 years (mean 8.5
years)
Total: 83; 40 in the
probiotic group, 43
in the placebo
group
Two lozenges with S. salivarius (each
lozenge 3.6 × 109 CFU of strain), two
times a day, one in the morning and
one at night, for three months
Placebo. Lozenges
with identical
appearance and
taste, without
probiotics
3 months Salivasamples
OR* 1.427 95% CI
(0.667–3.054)
Hatakka et al.
2007 [53] RCT
Homes and sheltered
housing units City:
Helsinki Country:
Finland
Elderly people, aged
70–100 years
Total: 192; 92 in the
probiotic group, 100
in the placebo
group.
Daily 50 g of Emmental-type
probiotic cheese divided into two
portions, with Lactococcus lactis and
Lactobacillus helveticus as starter
cultures and 107 CFU/g of each
probiotic strain: L. rhamnosus GG
(ATCC 53103), L. rhamnosus LC705,
and Propionibacterium freudenreichii
ssp. shermanii JS
Daily 50 g of edam
type cheese,
divided into two
portions, with
Lactococcus lactis as
starter culture
without the
addition of other
probiotic strains
16 weeks Salivasamples
OR 0.505 95% CI
(0.263–0.970)OR
calculated for a
cut-off of Candida
≥104 CFU/ml
Ishikawa et al.
2015 [54] RCT
Patients seeking dental
treatment (complete
denture) at the School
of Dentistry, University
of São Paulo City: São
Paulo Country: Brazil
Denture wearers
harboring Candida
spp. in the oral cavity
with no clinical
symptoms, aged
(mean) 61.8 ± 8.5
years
Total: 55. 30 in the
probiotic group. 25
in the placebo
group
1 capsule/day containing lyophilized
cultures (obtainedfrom
HardiStrain®– Probiotics) of L.
rhamnosus HS111, L. acidophilus
HS101, and Bifidobacterium bifidum
combined in equal amounts,
reaching 108 CFU (3.3 × 107 CFU of
each) per capsule
Placebo 1
capsule/day with
same characteristics
as the probiotic
product, but
without the
probiotic bacteria
5 weeks
Palatal
mucosal
samples
OR 0.066 95% CI
(0.013–0.338)OR
calculated for a
cut-off of Candida
≥104 CFU/ml
Keller et al.
2018 [55] RCT
Clinic for oral medicine
City: Copenhagen
Country: Denmark
Patients attending the
Clinic for Oral
Medicine, aged
median (67) years,
with diagnosis of oral
lichen planus
Total: 22.9 in the
probiotic group, 13
in the placebo
group
Pre-treatment: all patients were
treated with the current
conventional treatment regimens at
the Clinic for Oral Medicine,
including those who required
additional conventional treatment
during the 1-year study period
Patients diagnosed with oral
candidiasis were treated
withnystatin, patients without oral
candidiasis were treated with
steroid, fluocinolone acetonide gel
0.025% Treatment: probiotic
lozenges containing two strains of
the probiotic bacteria L. reuteri (DSM
17938 and ATCC PTA 5289)
dissolved intra-orally three times
daily (morning, noon, and evening
just before bedtime) for 16 weeks
Pre-treatment: the
same of
intervention group
Treatment: placebo
lozenges without
probiotic bacteria
16 weeks Salivasamples
OR 0.952 95% CI
(0.125–7.275)OR
calculated with
cut-off Candida
carriage yes/no
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Table 2. Cont.
Reference Study Design Setting Studied Population No. of Participants Intervention Comparison Follow-up Sample Type Outcome
Kraft- Bodi et
al. 2015 [56] RCT
Nursing homes.
Country: south of
Sweden
Elderly people, aged
(mean) 88 years
Total: 174; 84 in the
probiotic group, 90
in the placebo
group
2 lozenges daily the morning and in
the early evening, containing a
minimum of 108 live bacteria of each
strain of the probiotic bacterium
Lactobacillus reuteri (DSM 17938 and
ATCC PTA 5289; Prodentis™,
Biogaia®AB, Lund, Sweden)
Placebo lozenges
without active
bacteria
12 weeks Salivasamples
OR 0.505 95% CI
(0.259–0.984)OR
calculated for a
cut-off of Candida
≥ 104 CFU/ml
Li et al. 2014
[57] RCT
Department of Oral
Medicine, West China
College of Stomatology,
Sichuan University
City: Sichuan Country:
China
Patients with
clinically and
microbiologically
proven
Candida-associated
stomatitis (detection
rate of Candida
albicans in the saliva
>102 CFU mL−1),
aged (mean, SD) 64 ±
10.75 years
Total: 65; 34 in the
probiotic group, 31
in the control group
Pre-treatment: administration orally
of 2% sodium bicarbonate solution
and then application of 2% nystatin
pasteTreatment: four lozenges
containing the mixture of B. longum
(5 × 106 CFU in 0.5 g of skim milk
powder per tablet), L. bulgaricus (5 ×
105 CFU in 0.5 g of skim milk
powder per tablet), and S.
thermophilus (5 × 105 CFU in 0.5 g of
skim milk powder per tablet)The
medication was applied three times
daily for 4 weeks.
2% sodium
bicarbonate
solution and 2%
nystatin paste
4 weeks Salivasamples
OR 0.176 95% CI
(0.044–0.710)OR
calculated for a
cut-off of Candida
≥102 CFU/mL
Lopez-Jornet
et al. 2018 [64]
Before–after
study
Clınica Odontologica
Universitaria Hospital
Morales MeseguerCity:
Murcia. Country: Spain
Patients, aged (mean)
71.2 years Total: 27
Lactobacillus reuteri DSM 17938
(German Culture Collection of
Microorganisms) and ATCC PTA
5289 (American Type Culture
Collection) (GUM Periobalance®,
Sunstar) one tablet per day for 28
days
28 days Salivasamples
OR 3.00095 %CI
(0.312–28.842)OR
calculated with a
cut-off of Candida
>102 CFU/mL
Mendonça
et al. 2012 [65]
Before–after
study
City: Taubaté Country:
Brazil
Healthy women aged
65 or older who lived
in the city of Taubaté,
SP, Brazil
Total: 42
1 g (content of 1 envelope) of the
probiotic Yakult LB®(Lactobacillus
casei and Bifidobacterium breve, 2 ×
107 to 109 and 5 × 107 to 109
CFU/mL, respectively), 3 times a
week, at the same hour, for 30 days
30 days Salivasamples
OR 0.400 95% CI
(0.078–2.062)OR
calculated with a
cut-off Candida
carriage yes/no
Miyazima
et al. 2017 [58] RCT
School of Dentistry,
University of São Paulo
City: São Paulo
Country: Brazil
Denture-wearing
patients seeking for
dental treatment
(complete denture),
aged (mean, SD) 64.4
±12.07 years
Total: 60; 20 in each
group (treatment 1,
treatment 2, control)
Treatment 1, T1 group: fresh cheese
added with probiotics containing 8
to 9 log CFU·g−1 of L. acidophilus
NCFMTreatment 2, T2 group: fresh
cheese added with probiotics
containing 8 to 9 log CFU·g−1 of L.
rhamnosus Lr-32
PlaceboControl
group (C group):
fresh cheese with
no added probiotics
8 weeks Mouth-rinsesamples
OR 0.464 95% CI
(0.155–1.392)OR
calculated for a
cut-off of Candida
≥103 CFU/mL
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Table 2. Cont.
Reference Study Design Setting Studied Population No. of Participants Intervention Comparison Follow-up Sample Type Outcome
Petti et al.
2001 [59] RCT Country: Italy
Adult volunteers,
aged (mean) 28.2
years
Total: 42; 20 in the
yoghurt group,
22 in the control
group
125 g of fruit yoghurt twice daily,
between breakfast and lunch, and
between lunch and dinnerThen,
2 weeks without yogurt intake
125 g of fruit
soybean ice cream
twice daily,
between breakfast
and lunch, and
between lunch and
dinner Then,
2 weeks without
soybean ice cream
intake
16 weeks Salivasamples
OR 1.167 95% CI
(0.335–4.060)OR
calculated for a
cut-off of Candida
between 3.5 and 7.6
× 102 CFU/mL
Rane et al.
2018 [62]
Before–after
study Country: India
Healthy complete
denture wearers,
aged ≥50 years
Total: 60; 20 in
group A (age 50–59
years), 20 in group
B (age 60–69 years),
20 in group C (age
≥ 70 years)
Once daily, 1 capsule content of
probiotic (Probiotic immune®,
Zenith nutrition) in the palatal
region of the cleaned maxillary
denture
5 weeks
Palatal
mucosa
samples
OR* group A 0.891
95% CI
(0.290–2.736)OR
group B 1.323 95%
CI (0.431–4.063)OR
group C 0.846 95%
CI (0.276–2.598)
Sutula et al.
2013 [63]
Before–after
study
Manchester
Metropolitan
University City:
Manchester. Country:
United Kingdom
Healthy dentate
volunteers, aged
(mean, SD) 32 ± 11.5
years
Total: 21
One bottle per day of drink milk
Yakult ®, containing a minimum of
6.5 × 109 viable cells of probiotic
L. casei strain Shirota, for 4 weeks
4 weeks Salivasamples
OR* 4.967 95% CI
(1.662–14.843)
* OR derived from the standardized mean difference (SMD) between the treatment and the control group, according to the Hasselblad and Hedges method [60].
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The 12 papers included in the analysis were published from 2001 to 2018. Eight studies were
RCTs [53–60], and four were pre–post intervention studies [62–65].
The sample size ranged from 21 to 192. The total number of participants was 843, with an age
between five and 100 years, with elderly people (70–100 years) being the most represented (n = 395).
Three studies included only denture wearers [54,58,62], and one study involved schoolchildren [60].
The patients were from 10 countries: Brazil, China, Denmark, Finland, India, Italy, New Zealand,
Sweden, and United Kingdom. Three studies were from Brazil [54,58,65].
The studies investigated a total of 16 strains (alone or in combination) of probiotics. The most
represented were Lactobacillus spp., followed by Bifidobacterium spp., Saccaromyces spp., and in one case
Propionibacterium spp., at doses from 5 × 105 to 5 × 109 CFU/mL one, two, or three times a day or less
frequently (such as three times a week or every two weeks). None of the studies included prebiotics
or synbiotics.
Most probiotics were given though lozenges or capsules, or with dairy products such as cheese,
milk, or yogurt in some studies.
The length of the follow-up ranged from a minimum of four weeks to a maximum of 16 weeks.
The reported outcomes measures were different among studies. Three studies reported the means
of CFU/mL, two studies reported the presence (yes/no) of Candida spp. carriage, and seven studies
reported the Candida spp. carriage (yes/no) based on different thresholds of Candida spp. counts (102,
103, or 104).
2.4. Evaluation of the Risk of Bias for RCTs
The results of the risk of bias evaluation are reported in Figure 2.
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In total, 50% of RCTs appropriately described the random sequence generation process, but only one
reported the allocation concealment in detail. In most studies (87.5%), participants and personnel were
blinded; in five studies, the outcome assessors were also blinded. Six studies out of eight had a low
risk of incomplete data, with only one (Hatakka et al. 2007 [53]) being classified as having a high risk
because 30% of participants dropped out during the study. Regarding selective reporting, one study
(Burton et al., 2003 [60]) was judged to have a high risk because, in the article, the outcome of interest
was incompletely reported. However, after e-mail contact with the authors, the reviewers received the
data required. Finally, the reviewers assigned high risk to Keller et al., 2018 [55], because, as declared
by authors, “fewer participants completed the study as projected, and the study was terminated before
completion because of recruitment problems”.
2.5. Evaluation of the Risk of Bias for Pre–Post Intervention Studies
On the basis of the quality appraisal criteria proposed by the NHLBI [68] for pre–post intervention
studies with no control group, the study by Lopez et al. (2018) [64] was classified as having poor
quality because the paper consisted of a correspondence letter which provided poor information about
the trial. The other three studies were susceptible to some bias, but not sufficient to invalidate the
results (Figure 3). Thus, they were assigned to the fair quality category.
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2.6. Meta-Analysis Results
The results of the Bayesian random-effects meta-analysis conducted on the 12 evaluated studies
are reported in the Figure 4.
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Overall, we estimated that the OC odds ratio in the treated patients was around 30% lower than
in the controls (OR = 0.71; 95% CrI: 0.37, 1.32). However, it should be noted that the 95% confidence
interval of the overall OR was not completely included in the beneficial effect region (OR < 1). The I2
index, with a posterior median of 56.3% (95% CrI: 6.0%, 84.4%), suggests the presence of a relevant
heterogeneity among studies.
When we restricted the meta-analysis to RCTs, a clear beneficial effect of treatment arose (Figure 5).
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Figure 5. Forest plot from the Bayesian random-effects meta-analysis on randomized controlled studies.
The estimated effect size was lower than in the previous analysis (OR = 0.53; 95% CrI: 0.27, 0.93),
but the precision of the esti ate was larger. As expected, this subset of studies appeared to be less
heterogeneous (posterior median of I2 = 32.2%; 95 CrI: 0.3%, 84.0%), even if a relevant discrepancy
between results was still present.
In a sensitivity analysis, we performed a stratified meta-analysis distinguishing between RCTs
performed on denture wearers and RCTs on non-denture wearers. The effect of treatment appeared to
be larger in denture wearers, ith an OR equal to 0.65 (95% CrI: 0.36, 1.17) for non-denture wearers
(Figure 6) versus an OR equal to 0.19 (95% CrI: 0.03, 1.29) for denture wearers.
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Figure 6. Forest plot from the Bayesian random-effects meta-analysis of the randomized controlled
studies on non-denture wearers.
However, in interpreting this result, we should account for the fact that the meta-analysis on
denture- earing patients relied on only two studies.
When, in a second sensitivity analysis, we excluded from the RCTs the study by Burton et al.
(2013) [60], which was conducted on schoolchildren, we observed a slight increase in effect size
(OR = 0.44; 95% CrI: 0.25, 0.73) and a reduction in I2 (posterior median of I2 = 7.0%; 95% CrI: 0.2%,
76.2%) (Figure 7).
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Figure 7. Forest plot from the Bayesian random-effects meta-analysis of the randomized controlled
studies on adults.
A summary of the meta-analyses results is presented in Table 3.
Table 3. Summary of the results from the Bayesian random-effect meta-analyses. CrI—credibility
interval.
Type of Meta-Analysis Meta-Analytic Estimate(OR) (95% CrI) I
2 (95% CrI)
All 12 studies 0.71 ( 37–1 2) 56.3 (6.0–84 4)
Only RCTs 0.53 ( .27– .9 ) 32.2 (0.3–84.0)
RCTs with non-denture wearers 0.65 (0.36–1.17) 17.6 (0.3–81.8)
RCTs with denture wearers 1 0.19 (0.03–1.29)
RCTs with adult patients 0.44 (0.25–0.73) 7.0 (0.2–76.2)
1 Results from the fixed-effects model.
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From the inspection of the funnel plot, no evidence of publication bias arose (Figure 8).
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If we focus on RCTs on non-denture wearers, a larger effect was reported in Li et al. (2014) [60], where
the treated patients received three doses per day instead of one or two. Three doses were administered
also in Keller et al. 2018 [55], but this study was affected by recruitment problems, and the result relied
on a very small number of subjects.
A second relevant source of heterogeneity was related to the fact that different microbial probiotic
strains could have different effects on the reduction of Candida spp. counts [58]. For example, Matsubara
and colleagues found that, in a mice model, the treatment with Lactobacillus rhamnosus Lr-32 was more
effective than the treatment with Lactobacillus acidophilus on the Candida spp. colonization levels [51].
Unfortunately, as the number of studies collected from the literature was too small to build a network
of comparisons involving multiple treatments, we considered all treatments as having the same effect,
which was clearly a very strong assumption.
Therefore, summarizing the obtained results, we can conclude that probiotics have a protective
role in the Candida spp. infection and especially colonization. As previously reported, the anti-Candida
properties can be explained in different ways, such as (a) through co-aggregation, modification of
oral pH, and production of H2O2 [45], (b) through releasing high amounts of lactic acid [47], and (c)
through the complete inhibition of fungal biofilms [48,49]. However, these positive effects are highly
linked to the administration method, the dosage, and the used probiotics strains. In addition, we did
not find studies on prebiotics and synbiotics eligible for our meta-analysis. The effect of these products
on the oral candidiasis must be better investigated in order to discover novel antifungal effects. In fact,
some studies demonstrated that the combination of probiotics and prebiotics (synbiotics) can be very
effective in infections [79,80].
Our results suggest planning a new clinical study to evaluate the real effectiveness of probiotics
treatment in Candida spp. infection. The focal points of the study should be (1) the age stratification
of the patients (old or adult), (2) the administration method (topic or oral), the type (lozenges or
capsules), the dosage, and the treatment duration, (3) the choice of appropriate probiotic strains
(Lactobacillus spp., Bifidobacterium spp., Saccaromyces spp., or Propionibacterium spp.), and (4) the length
of the patient follow-up.
Our study also had other limitations. Firstly, the number of studies included in the meta-analysis
was small, in particular when we focused on the RCTs. Secondly, some of the studies had a high risk of
bias. Thirdly, with the aim of providing an overview of the literature, we did not apply strong exclusion
criteria, at the price of a larger heterogeneity among studies. For the same reason, we sometimes had to
adopt approximations to obtain a common comparable effect measure (OR) from the results reported
in the original papers; this could have introduced a certain degree of bias in the meta-analysis.
4. Conclusions
In conclusion, our meta-analysis is one of the first that critically evaluated the impact of probiotics
in oral candidiasis and, on the basis of the meta-analysis results, despite the high heterogeneity among
studies, we are confident in declaring that the treatment can have a beneficial effect on reducing oral
Candida spp. counts.
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